These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23181502)

  • 1. Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
    Liu Y; Zhang W; Li L; Salvador LA; Chen T; Chen W; Felsenstein KM; Ladd TB; Price AR; Golde TE; He J; Xu Y; Li Y; Luesch H
    J Med Chem; 2012 Dec; 55(23):10749-65. PubMed ID: 23181502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Jacobsen S; Magolda RL; Pangalos M; Robichaud AJ
    J Med Chem; 2010 Feb; 53(3):1146-58. PubMed ID: 19968289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.
    Liu J; Chen W; Xu Y; Ren S; Zhang W; Li Y
    Bioorg Med Chem; 2015 May; 23(9):1963-74. PubMed ID: 25842365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Barnes K; Johnson M; Hui Y; Turner J; Hu Y; Wagner E; Fan K; Olland A; Bard J; Robichaud AJ
    J Med Chem; 2009 Oct; 52(20):6314-23. PubMed ID: 19757823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iminoheterocycle as a druggable motif: BACE1 inhibitors and beyond.
    Zhu Z
    Trends Pharmacol Sci; 2012 May; 33(5):233-40. PubMed ID: 22480948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based discovery of BACE1 inhibitors using functional assays.
    Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J
    Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors.
    Tagad HD; Hamada Y; Nguyen JT; Hidaka K; Hamada T; Sohma Y; Kimura T; Kiso Y
    Bioorg Med Chem; 2011 Sep; 19(17):5238-46. PubMed ID: 21803585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acylguanidines as small-molecule beta-secretase inhibitors.
    Cole DC; Manas ES; Stock JR; Condon JS; Jennings LD; Aulabaugh A; Chopra R; Cowling R; Ellingboe JW; Fan KY; Harrison BL; Hu Y; Jacobsen S; Jin G; Lin L; Lovering FE; Malamas MS; Stahl ML; Strand J; Sukhdeo MN; Svenson K; Turner MJ; Wagner E; Wu J; Zhou P; Bard J
    J Med Chem; 2006 Oct; 49(21):6158-61. PubMed ID: 17034121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
    Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
    Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design.
    Mok NY; Chadwick J; Kellett KA; Casas-Arce E; Hooper NM; Johnson AP; Fishwick CW
    J Med Chem; 2013 Mar; 56(5):1843-52. PubMed ID: 23374014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
    Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
    J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
    Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
    J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
    Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
    J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.